Eli Lilly and Company (NYSE:LLY) Shares Up 2.2% – What’s Next?

Eli Lilly and Company (NYSE:LLY) traded up 2.2% during mid-day trading on Thursday . The company traded as high as $1,170.12 and last traded at $1,161.75. 2,751,941 shares traded hands during mid-day trading, a decline of 14% from the average session volume of 3,215,496 shares. The stock had previously closed at $1,136.37.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s Q1 2026 results showed 55.5% revenue growth and a guidance increase, reinforcing its lead in the GLP-1 obesity market versus Novo Nordisk, which posted weaker results and is cutting jobs. Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy
• Positive Sentiment: Analysts raised earnings expectations and price targets after Lilly’s recent data releases, including a Jefferies target increase to $1,350 and a higher FY2026 EPS estimate from Erste Group, signaling continued confidence in growth. Eli Lilly and Company Given Consensus Recommendation of Moderate Buy by Analysts
• Positive Sentiment: The FDA approved extended every-8-weeks maintenance dosing for EBGLYSS, expanding Lilly’s dermatology franchise and improving convenience for patients, which could support broader adoption. FDA Ebglyss Decision Adds New Thread To Eli Lilly Growth Story
• Positive Sentiment: New Phase 2 chronic pain trials and positive Foundayo weight-loss data add to Lilly’s pipeline depth beyond obesity and diabetes, giving investors more reasons to expect long-term growth. Eli Lilly Expands Chronic Pain Pipeline With New Osteoarthritis Trial
• Neutral Sentiment: Coverage articles and conference commentary highlighted Lilly as a defensive healthcare name and a top pick in the market rotation out of tech, which helps sentiment but does not change fundamentals on its own. Zacks Investment Ideas feature highlights: Eli Lilly, Home Depot, Procter & Gamble and Starbucks
• Negative Sentiment: One potential headwind is that some U.S. employers are considering dropping GLP-1 obesity-drug coverage in 2027, which could pressure future demand and reimbursement for Lilly’s weight-loss products. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on LLY. CICC Research lifted their price objective on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research note on Wednesday, February 11th. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday. Cantor Fitzgerald raised their target price on Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the company an “overweight” rating in a report on Friday, May 1st. UBS Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Finally, Truist Financial reiterated a “buy” rating on shares of Eli Lilly and Company in a research note on Monday, February 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,227.74.

Eli Lilly and Company Stock Performance

The stock has a 50 day simple moving average of $989.96 and a two-hundred day simple moving average of $1,015.14. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The company has a market cap of $1.09 trillion, a PE ratio of 41.27, a PEG ratio of 1.25 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the previous year, the firm earned $3.34 earnings per share. The firm’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts predict that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th were paid a dividend of $1.73 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.

Hedge Funds Weigh In On Eli Lilly and Company

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Eli Lilly and Company by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after purchasing an additional 1,006,885 shares during the last quarter. State Street Corp increased its position in shares of Eli Lilly and Company by 1.8% in the fourth quarter. State Street Corp now owns 35,361,916 shares of the company’s stock valued at $38,002,744,000 after buying an additional 635,358 shares in the last quarter. Capital Research Global Investors raised its stake in shares of Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after buying an additional 4,332,008 shares during the last quarter. Morgan Stanley boosted its position in shares of Eli Lilly and Company by 2.7% in the 4th quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock worth $16,757,510,000 after buying an additional 407,166 shares in the last quarter. Finally, Capital World Investors boosted its position in shares of Eli Lilly and Company by 0.4% in the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock worth $16,154,619,000 after buying an additional 61,851 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.